1 August 2020 in Diabetes, Metabolic Syndrome and Obesity
Objective: Recent findings have associated insulin resistance and obesity with increased gut permeability. However, it still remains unclear whether obesity may be the underlining factor for the association between gut permeability and insulin resistance. This study investigated the relationship between gut permeability, measures of obesity, and markers of insulin resistance in young adults. Materials and Methods: A cross-sectional quantitative study which enrolled 151 young South African adults was conducted. Anthropometric measurements were performed to assess obesity. Adiponectin, leptin, and zonulin, a marker for gut permeability, were assayed. Insulin and fasting glucose were assayed and used to determine insulin resistance (HOMA-IR), insulin sensitivity (%S) and beta cell function (%B). Results: Decreased adiponectin and increased leptin were associated (p< 0.05) with obesity. HOMA-IR inversely correlated (p< 0.05) with adiponectin but positively with leptin to adiponectin (Lept/ADP) ratio (p< 0.05) in females. Markers of insulin resistance were not associated (p> 0.05) with obesity. Overweight/obese (O/O) females had a significantly (p< 0.01) higher zonulin concentration than lean females. Zonulin positively associated (p< 0.05) with body mass index and visceral fat, as well as with HOMA-IR and insulin concentration. Lept/ADP ratio, an inflammatory marker, was associated with risk of insulin resistance. Increased insulin, a maker for insulin resistance, was associated with risk of gut permeability. Conclusion: Insulin resistance was associated with gut permeability without a direct influence by obesity in young adults. The lack of relationship between obesity and insulin resistance was possibly mediated by the contribution of obesity to gut permeability. This finding suggests that gut permeability may be a potential independent risk factor for the development of insulin resistance in healthy obese young adults.
26 November 2025 in HIV Research & Clinical Practice
The relative contributions of HIV infection, antiretroviral therapy (ART), and classical metabolic risk factors to the link between gut permeability and insulin resistance (IR) remain unclear. To examine the relationship between gut permeability, systemic inflammation, and insulin resistance among people with HIV in Mthatha, South Africa. A cross-sectional study was conducted with 226 participants: 82 HIV-, 64 HIV+ART-, and 80 HIV+ART+. Anthropometry and lipid profiles were assessed to evaluate obesity and dyslipidaemia. Gut permeability (intestinal fatty acid binding protein, IFABP) and inflammation (soluble CD14, sCD14) were measured, alongside fasting insulin and glucose to calculate HOMA-IR. Overweight/obesity was more prevalent among ART-treated people with HIV (HIV+ART+) than ART-naïve participants (HIV+ART-). Both HIV-positive groups showed increased gut permeability and inflammation compared with controls (p < 0.05). In ART-naïve people with HIV, gut permeability was associated with triglycerides, while in ART-treated people with HIV it was linked to gut-associated inflammation and markers of IR (fasting glucose, TG/HDL-c ratio). HOMA-IR correlated with obesity and dyslipidaemia (total cholesterol, LDL) in ART-naïve participants but was associated only with gut-associated inflammation in ART-treated participants (p < 0.05, respectively). Gut permeability is linked to insulin resistance in ART-treated people with HIV, independent of obesity and dyslipidaemia. This highlights a novel pathway for intervention to reduce NCD burden.